6 results on '"Carboni, Filippo"'
Search Results
2. Structure-based glycoconjugate vaccine design: The example of Group B Streptococcus type III capsular polysaccharide.
- Author
-
Carboni, Filippo and Adamo, Roberto
- Subjects
STREPTOCOCCUS agalactiae ,MICROBIAL polysaccharides ,SURFACE plasmon resonance ,STREPTOCOCCUS thermophilus ,MAGNETIZATION transfer ,X-ray crystallography ,STREPTOCOCCUS - Abstract
• Elucidation of minimal glycan epitopes is key for vaccine design. • Application of structural glycobiology to conjugate vaccines enables identification of relevant glycan epitopes. • We solved by X-ray crystallography the highly complex epitope from GBSIII capsular polysaccharide complexed with a Fab. • Based on this information a synthetic glycan was designed and protein conjugate to induce a strong immune response. • This approach can be extended to other GBS polysaccharides as well as glycans from other pathogens. Microbial surface polysaccharides are important virulence factors and targets for vaccine development. Glycoconjugate vaccines, obtained by covalently linking carbohydrates and proteins, are well established tools for prevention of bacterial infections. Elucidation of the minimal portion involved in the interactions with functional antibodies is of utmost importance for the understanding of their mechanism of induction of protective immune responses and the design of synthetic glycan based vaccines. Typically, this is achieved by combination of different techniques, which include ELISA, glycoarray, Surface Plasmon Resonance in conjunction with approaches for mapping at atomic level the position involved in binding, such as Saturation Transfer NMR and X-ray crystallography. This review provides an overview of the structural studies performed to map glycan epitopes (glycotopes), with focus on the highly complex structure of Group B Streptococcus type III (GBSIII) capsular polysaccharide. Furthermore, it describes the rational process followed to translate the obtained information into the design of a protective glycoconjugate vaccine based on a well-defined synthetic glycan epitope. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Evaluation of Immune Responses to Group B Streptococcus Type III Oligosaccharides Containing a Minimal Protective Epitope.
- Author
-
Carboni, Filippo, Angiolini, Francesca, Fabbrini, Monica, Brogioni, Barbara, Corrado, Alessio, Berti, Francesco, Adamo, Roberto, and Margarit, Immaculada
- Subjects
- *
STREPTOCOCCUS agalactiae , *OLIGOSACCHARIDES , *IMMUNE response , *CARRIER proteins , *MONOCLONAL antibodies , *STREPTOCOCCAL disease prevention , *RESEARCH , *ANIMAL experimentation , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *STREPTOCOCCUS , *COMPARATIVE studies , *MOLECULAR structure , *ANTIGENS , *BACTERIAL vaccines , *MICE - Abstract
Recent structural studies demonstrated that the epitope recognized by a monoclonal antibody representative of the protective response against the type III group B Streptococcus polysaccharide was comprised within 2 of the repeating units that constitute the full-length native structure. In the current study, we took advantage of this discovery to design a novel vaccine based on multivalent presentation of the identified minimal epitope on a carrier protein. We show that highly glycosylated short oligosaccharide conjugates elicit functional immune responses comparable to those of the full-length native polysaccharide. The obtained results pave the way to the design of well-defined glycoconjugate vaccines based on short synthetic oligosaccharides. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera.
- Author
-
Fabbrini, Monica, Rigat, Fabio, Rinaudo, C. Daniela, Passalaqua, Irene, Khacheh, Sceida, Creti, Roberta, Baldassarri, Lucilla, Carboni, Filippo, Anderloni, Giulia, Rosini, Roberto, Maione, Domenico, Grandi, Guido, Telford, John L., and Margarit, Immaculada
- Subjects
STREPTOCOCCUS agalactiae ,NEONATAL sepsis ,MENINGITIS ,NEONATAL infections ,IMMUNOGLOBULIN G - Abstract
Background. Group B Streptococcus (GBS) is a major cause of neonatal sepsis and meningitis. A vaccine targeting pregnant women could protect infants through placentally transferred antibodies. The association between GBS maternal antibody concentrations and the risk of neonatal infection has been investigated in US and African populations. Here we studied naturally acquired immunoglobulin G (IgG) responses to GBS capsular polysaccharides (CPS) and pilus proteins in European pregnant women. Methods. Maternal sera were prospectively collected in 8 EU countries from 473 GBS non-colonized and 984 colonized pregnant women who delivered healthy neonates and from 153 mothers of infants with GBS disease. GBS strains from these colonized women and infected infants were obtained in parallel and their capsular and pilus types were identified by serological and molecular methods. Maternal serum concentrations of IgG anti- Ia, -Ib, -III and -V polysaccharides and anti-BP-1, -AP1-2a and -BP-2b pilus proteins were determined by enzyme-linked immunosorbent assay. Antibody functional activity was quantified by Opsonophagocytic Killing Assay. Results. Antibody levels against CPS and pilus proteins were significantly higher in GBS colonized women delivering healthy babies than in mothers of neonates with GBS disease or non-colonized women. Moreover, maternal anti-capsular IgG concentrations showed a significant correlation with functional titers measured by Opsonophagocytic Killing Assay. Conclusions. Maternal anti-capsular IgG concentrations above 1 μg/mL mediated GBS killing in vitro and were predicted to respectively reduce by 81% (95% confidence interval, 40%-100%) and 78% (45%-100%) the risk of GBS Ia and III early-onset disease in Europe. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. Antibody‐mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen.
- Author
-
Fantappiè, Laura, de Santis, Micaela, Chiarot, Emiliano, Carboni, Filippo, Bensi, Giuliano, Jousson, Olivier, Margarit, Immaculada, and Grandi, Guido
- Abstract
Background: Outer membrane vesicles (OMVs) from Gram‐negative bacteria are gaining increasing attention as vaccine platform for their built‐in adjuvanticity and for their potential use as carriers of heterologous antigens. These 2 properties offer the opportunity to make highly effective, easy to produce multi‐valent vaccines. OMVs can be loaded with foreign antigens by targeting protein expression either to the outer membrane or to the periplasm of the OMV‐producing strain. Periplasmic expression is simple and relatively efficient but leads to the accumulation of recombinant antigens in the lumen of OMVs and the ability of OMVs carrying internalized antigens to induce antigen‐specific antibody responses has been only marginally investigated and is considered to be sub‐optimal. Methods: We have systematically analyzed in qualitative and quantitative terms antibody responses induced by OMVs carrying different heterologous antigens in their lumen. Group A Streptococcus (GAS) Slo, SpyCEP, Spy0269 and Group B Streptococcus (GBS) SAM_1372 were fused to the OmpA leader sequence for secretion and expressed in Escherichia coli. OMVs from the recombinant strains were purified and tested for immunogenicity and protective activity. Results: All proteins were incorporated into the OMVs lumen in their native conformation. Upon mice immunization, OMVs induced high functional antibody titers against the recombinant proteins. Furthermore, immunization with Slo‐OMVs and SpyCEP‐OMVs protected mice against GAS lethal challenge. Conclusions: The efficiency of antigen delivery to the vesicular lumen via periplasmic expression, and the surprisingly high immunogenicity and protective activity of OMVs carrying internalized recombinant antigens further strengthens the potential of OMVs as vaccine platform. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Design of a novel vaccine nanotechnology-based delivery system comprising CpGODN-protein conjugate anchored to liposomes.
- Author
-
Chatzikleanthous, Despo, Schmidt, Signe Tandrup, Buffi, Giada, Paciello, Ida, Cunliffe, Robert, Carboni, Filippo, Romano, Maria Rosaria, O'Hagan, Derek T., D'Oro, Ugo, Woods, Stuart, Roberts, Craig W., Perrie, Yvonne, and Adamo, Roberto
- Subjects
- *
CATIONIC lipids , *STREPTOCOCCUS agalactiae , *DRUG delivery systems , *NANOMEDICINE , *VACCINES - Abstract
Although the well-known Toll like receptor 9 (TLR9) agonist CpGODN has shown promising results as vaccine adjuvant in preclinical and clinical studies, its in vivo stability and potential systemic toxicity remain a concern. In an effort to circumvent these issues, different strategies have been employed to increase its stability, localise action and reduce dosage. These include conjugation of CpGODN with proteins or encapsulation/adsorption of CpGODN into/onto liposomes, and have resulted in enhanced immunopotency compared to co-administration of free CpGODN and antigen. Here, we designed a novel delivery system of CpGODN based on its conjugation to serve as anchor for liposomes. Thiol-maleimide chemistry was utilised to covalently ligate the Group B Streptococcus (GBS) GBS67 protein antigen with the CpGODN TLR9 agonist. This treatment did not alter protein's ability to be recognised by specific antibodies or the CpGODN to function as a TLR9 agonist. Due to its negative charge, the protein conjugate readily electrostatically bound cationic liposomes composed of 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol and dimethyldioctadecylammonium bromide (DDA). The novel cationic liposomes-protein conjugate complex (GBS67-CpGODN+L) shared similar vesicle characteristics (size and charge) compared to free liposomes but exhibited different structure and morphology. Following intramuscular immunisation, GBS67-CpGODN+L formed a vaccine depot at the injection site and induced a remarkable increase of functional immune responses against GBS compared to the simple co-administration of GBS67, CpGODN and liposomes. This work demonstrates that the conjugation of CpGODN to GBS67 in conjunction with adsorption on cationic liposomes, can promote co-delivery leading to the induction of a multifaceted immune response at low antigen and CpGODN doses. Our findings highlight the potential for harnessing the immunostimulatory properties of different adjuvants to develop more effective nanostructure-based vaccine platforms. Unlabelled Image • Delivery system combines synergistically protein-adjuvant conjugate and liposomes. • Immune response was dramatically improved compared to previously published data. • Pathogen Group B Streptococcus was used as model for which there is no vaccine yet. • The methodology could be extended to other agonists/adjuvant liposome formulations. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.